Catalyst Health Economics Consultants

Oncology (Including Haematology and Palliative Care)

1. Decision model for the cost of using opioids to treat cancer pain.

Presented at the EORTC First European Conference on the Economics of Cancer, Brussels, November 1997 and published in European Journal of Cancer 1997; 33(Suppl 9): S18.

2. Economic evaluation of using prophylactic clodronate to treat multiple myeloma.

Presented at the EORTC First European Conference on the Economics of Cancer, Brussels, November 1997 and published in European Journal of Cancer 1997; 33(Suppl 9): S25.

3. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids.

Author: JF Guest, WM Hart & RF Cookson.
Source: PharmacoEconomics, 1998; 14(3): 285-297.

View Abstract

4. Economic impact of using clodronate in the management of patients with multiple myeloma.

Presented at the 38th Meeting of the British Society for Haematology, Glasgow, April 1998 and at the ISH-EHA Combined Haematology Congress, Amsterdam, July 1998.

5. Cost-effectiveness of amphotericin B plus G-CSF compared to amphotericin B in the treatment of a presumed deep-seated fungal infection in neutropenic patients in the UK.

Authors: TN Flynn, SM Kelsey, DL Hazel & JF Guest.
Source: Blood 1998; 92(10) Suppl 1 (part 2 of 2): Abstract no: 3746.

6. Cost-effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

Authors: TN Flynn, SM Kelsey, DL Hazel & JF Guest.
Source: PharmacoEconomics 1999; 16(5,2): 543-550

View Abstract

7. The effect of treatment choices on the total cost of palliative care.

Author: R Twycross, M Fallon, K Sharma, C Hartley, JF Guest, WM Hart & E Wager.
Source: European Journal of Palliative Care, 1999; 6(3): 94-97

8. Economic impact of using clodronate in the management of patients with multiple myeloma.

Authors: NJ Bruce, EV McCloskey, JA Kanis & JF Guest.
Source: British Journal of Haematology. 1999; 104: 358-364.

View Abstract

9. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors: EV McCloskey, JF Guest & JA Kanis.
Source: Drugs 2001; 61 (9): 1253-1274

View Abstract

10. Treatment patterns and resource costs of palliative care for advanced cancer patients starting strong opioid treatment with 12-hourly sustained-release morphine or transdermal fentanyl.

Presented at the 10th World Congress on Pain, San Diego, August 2002.

View pdf

11. A comparison of the resources used in advanced cancer care between two different strong opioids: An analysis of naturalistic practice in the UK.

Authors: JF. Guest, FJ Ruiz, J Russ, R Das Gupta, A Mihai & M Greener.
Source: Current Medical Research and Opinion. 2005; 21(2): 271-280

View Abstract

12. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.

Authors: JF Guest, A Davie, J Clegg and E McCloskey.
Source: Current Medical Research and Opinion. 2005; 21(5):805-15.

View Abstract

13. Cost implications of post-surgical morbidity following blood transfusion in cancer patients undergoing elective colorectal resection: an evaluation in the US hospital setting.

Authors: JF Guest, FJ Ruiz, R Tang, J-Y Wang, CR Changchien, S Wexner and MA Choti.
Source: Current Medical Research and Opinion. 2005; 21(3): 447-455.

View Abstract

14. Costs and consequences of using pamidronate compared with zoledronic acid in managing breast cancer patients in the UK.

Presented at the 10th Congress of the European Association of Hospital Pharmacists, Lisbon, March 2005

15. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK.

Authors: JF Guest, FJ Ruiz, MJ Greener and IF Trotman.
Source: European Journal of Cancer Care. 2006; 15:65-73.

View Abstract

16. Cost-effectiveness of pentostatin compared to cladribine in the management of hairy cell leukaemia in the UK.

Presented at the 49th meeting of the British Society of Haematology, Brighton, April 2009.

17. A literature review on the clinical and economic outcomes attributable to first-line treatment for chronic myeloid leukemia with imatinib mesylate and bone marrow transplantation.

Presented at the 12th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Paris, October 2009.

View pdf

18. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.

Author: JF Guest, H Smith, E Sladkevicius & G Jackson.
Source: Clinical Therapeutics 2009; 31(2): 2398-2415.

View Abstract

19. Modelling the net resource implications and budget impact of using generic docetaxel instead of branded docetaxel in Spain.

Author: E Sladkevicius, D Lopez & JF Guest.
Source: Journal of the European Association of Hospital Pharmacists 2010; 4(2): 16-21.

View Abstract

20. Utility values for chronic myelogenous leukaemia chronic phase health states from the general public in the United Kingdom.

Presented at the 13th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Prague, November 2010.

View pdf

21. Cost-effectiveness of chemotherapies for advanced soft tissue sarcoma in five European countries.

Presented at the European CanCer Organisation (ECCO) Congress, Stockholm, September 2011.

22. Utility values for chronic myelogenous leukaemia chronic phase health states from the general public in the United Kingdom.

Author: JF Guest, N Naik, E Sladkevicius, J Coombs, EJ Gray.
Source: Leukemia & Lymphoma 2011; 53(5):928-933.

View Abstract

23. Economic evaluation of cancer treatments for advanced soft tissue sarcoma.

Presented at the 16th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), Beijing, September 2012.

24. Utility values for advanced soft tissue sarcoma health states from the general public in the United Kingdom.

Author: JF Guest, E Sladkevicius, N Gough, M Linch, R Grimer.
Source: Sarcoma 2013; http://dx.doi.org/10.1155/2013/863056 [Epub].

View Abstract

25. Utility values for specific chronic myelogenous leukaemia (CML) chronic phase health states elicited from the general public in the United Kingdom.

Presented at the 18th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), New Orleans, May 2013.

26. Cost-effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain and Sweden.

Author: JF Guest, M Panca, E Sladkevicius, N Gough, M Linch.
Source: Sarcoma 2013; 725305. doi: 10.1155/2013/725305. Epub 2013 Nov 3.

View Abstract

27. Utility values for specific chronic myelogenous leukaemia chronic phase health states from the general public in the United Kingdom.

Author: JF Guest, EJ Gray, T Szczudlo, M Magestro.
Source: Leukemia & Lymphoma 2014;55(8):1870-5.

View Abstract


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018